Araştırma Makalesi
Koroner Arter Hastalığı Bulunan Obez Hastalarda Adipor1, Adipor2 Ve Adipoq Genetik Varyasyonların Etkisinin İncelenmesi
Öz
Amaç:
Obezite, son yıllarda dünya çapında en büyük sağlık problemlerinden biri haline
gelmiştir ve insidansı gittikçe artmaktadır. Gelişmiş ülkelerde yapılan
çalışmalara erişkinlerin %33’ünün, çocuk ve gençlerin ise %20-27’sinin obez
olduğunu göstermektedir. Türkiye’deki prevelansı %22,3 olarak bulunmuştur. Oran
kadınlarda %29,9, erkeklerde ise %12,9 olarak gösterilmiştir Aterosklerotik
kalp hastalığı, koroner kalp hastalığı yada iskemik kalp hastalığı olarak ta
bilinen koroner arter hastalığı kalp hastalığının en sık görülen şeklidir.
Hastalığın temel sebebi kalbi besleyen damarların iç duvarında plakların oluşması
ve oluşan bu plaklar sayesinde damar lümeninin daralarak kalbe giden kan miktarının
azalmasıdır. Risk faktörleri arasında plazma kolesterol düzeylerinde artış,
hipertansiyon, diyabet, obezite, insulin direnci, hiperinsulinemi, sigara kullanımı,
hiperfibrinojenemi, yaş, erkek cinsiyeti yer almaktadır. Adiponektin, gen
transkript-1 (apM1) gen bölgesin¬de kodlanan, 244 aminoasit içeren, bir
glikoproteindir. Beyaz yağ dokusu, özellikle de viseral yağ dokusundan
salgılanır. Plazmada kollajen I, III, V 'e bağlanır. Adiponektin glukoz regülasyonu
ve yağ asidi katabolizması gibi bir çok metabolik süreci düzenleyen protein yapıda
bir hormondur. Tez çalışmamızda ADİPOR1, ADİPOR2 VE ADİPOQ gen polimorfizmlerinin
tespit edilmesi ve hastalığa olan etkilerinin belirlenmesi amaçlanmaktadır. Gereç
ve Yöntem. Çalışmamızda ADİPOR1, ADİPOR2 VE ADİPOQ Gen Polimorfizmine uygun
protokolle PZRRFLP teknikleri kullanılarak belirlenmiştir. Bulgu ve sonuç:
ADİPOR2 AT genotipi (OR:2.056 (1.334-3.171) ve T alleli (OR:1.494; 1.159-1.926)
taşıma hastalarda kontrollere oranla yüksek. Hasta ve kontrol grupları arasında
ADIPOQ TT-TG-GG, ADIPOR1 AA-AG-GG, ADIPOR2 AAAT- TT gen polimorfizmleri
açısından çoğu klinik parametreler açısından anlamlı fakat daha ileri
aşamalarda istatistiki çalışma yapılacaktır.
Anahtar Kelimeler
Kaynakça
- 1. Shin Jh, Kim Jh, Lee Wy, Shim Jy. “The Expression Of Adiponectin Receptors And The Effects Of Diponectin And Leptin On Airway Smooth Muscle Cells.” Yonsei Med J. 2008 Oct 31;49(5):804-10. 2. Bringham Cl, Muller Jl, Palupu A, Spinelli Jj, Anis Aa, 1999 “The Cost Of Obesity İn Canada.“ Canadian Medical Association Journal. 160:483-488 3. Kopelman Pg., 2000. “Obesity As A Medical Problem.” Nature 6;404(6778):635-643 4. Coşkun H., 2002. “Türkiye’deki Obezite Sıklığı(Prevelansı)” 5. Farmer J.A., Gotto A.: “Risk Factor For Coronary Artery Disease.” In: Braunwald Heart Disease A Textbook Of Cardiovascular Medicine. 4th Ed An Hbj International Edition, Volume 1, Chapter 37, 1125-55, 1992. 6. Ross R.: “The Pathogenesis Of Atherosclerosis.” In : Braunwald Heart Disease A Textbook Of Cardiovascular Medicine. 4th Edition An Hbj International Edition, Volume 1, Chapter 36, 1106-24, 1992. 7. Havel Pj: “Control Of Energy Homeostasis And İnsulin Action By Adipocyte Hormones: Leptin, Acylation Stimulating Protein, And Adiponectin.” Curr Opin Lipidol 13: 51-59, 2002 8. Clasen R, Schupp M, Foryst- Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U. “Ppargamma-Activating Angiotensin Type-1 Receptor Blockers İnduce Adiponectin.” Hypertension. 2005 Jul;46(1):137-43. Epub 2005 Jun 6. 9. Haluzík M, PařÍzková J, Haluzík MM: “Adiponectin And İts Role İn The Obesity-İnduced İnsulin Resistance And Related Complications.” Physiol Res 53: 123-129, 2004b. 10. Steppan Cm, Baıley St, Bhat S, Brown Ej, Banerjee Rr, Wrıght Cm, Patel Hr, Ahıma Rs, Lazar Ma: “The Hormone Resistin Links Obesity To Diabetes.” Nature 409: 307-312, 2001. 11. Hotta K, Funahashı T, Arıtay, Takahashı M, Matsuda M, Okamoto Y, Iwahashı H, Kurıyama H, Ouchı N, Maeda K, Nıshıda M, Kıhara S, Sakaı N, Nakajıma T, Hasegawa K, Muraguchı M, Ohmoto Y, Nakamura T, Yamashıta S, Hanafusa T, Matsuzawa Y: “Plasma Concentrations Of A Novel, Adipose-Specific Protein, Adiponectin, İn Type 2 Diabetic Patients”. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000. 12. Arıtay, Kıhara S, Ouchı N, Takahashı M, Maeda K, Mıyagawa J, Hotta K, Shımomura I, Nakamura T, Mıyaoka K, Kurıyama H, Nıshıda M, Yamashıta S, Okubo K, Matsubara K, Muraguchı M, Ohmoto Y, Funahashı T, Matsuzawa Y: “Paradoxical Decrease Of An Adipose-Specific Protein, Adiponectin, İn Obesity.” Biochem Biophys Res Commun 257: 79-83, 1999. 13. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. 85 AZİZ SANCAR DENEYSEL TIP ARAŞTIRMA ENSTİTÜSÜ DERGİSİDİR “Adiponectin: A Key Adipocytokine İn Metabolic Syndrome.” Clin Sci (Lond). 2006;110: 267–278. 14. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsu- Zawa Y, Matsubara K. Cdna “Cloning And Expression Of A Novel Adipose Specific Collagen-Like Factor, Apm1 (Adipose Most Abundant Gene Transcript 1).” Biochem Biophys Res Commun 1996. 221:286-289. 15. Hu E, Liang P, Spiegelman Bm. “Adipoq İs A Novel Adipose Specific Gene Dysregulated İn Obesity”. J Biol Chem 1996. 271:10697-10703. 16. Vasseur F, Meyre D, Froguel P. “Adiponectin, Type 2 Diabe- Tes And The Metabolic Syndrome: Lessons From Human Genetic Studies.” Expert Rev Mol Med 2006. 8:1-12. 17. Kadowaki T, Yamauchi T. “Adiponectin And Adiponectin Receptors.” Endocr Rev 2005. 26:439-451. 18. Kharroubi I, Rasschaert J, Eizirik Dl, Cnop M. “Expression Of Adiponectin Receptors İn Pancreatic Cells.” Biochem Biophys Res Commun 2003. 312:1118-1122. 19. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno Nh, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, And Kadowaki T. “Cloning Of Adiponectin Receptors That Mediate Antidiabetic Metabolic Effects.” Nature 423: 762–769, 2003. 20. Ouchi, N., Kihara, S., Arita, Y. et al. (1999) “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.” Circulation 100, 2473–2476 21. Pischon, T., Girman, C. J., Hotamisligil, G. S., Rifai, N., Hu, F. B. and Rimm, E. B. (2004) “Plasma adiponectin levels and risk of myocardial infarction in men.” JAMA, J. Am. Med. Assoc. 291, 1730–1737 22. Schulze, M. B., Shai, I., Rimm, E. B., Li, T., Rifai, N. and Hu, F. B. (2005) “Adiponectin and future coronary heart disease events among men with type 2 diabetes.” Diabetes 54, 534–539 86 AZİZ SANCAR DENEYSEL TIP ARAŞTIRMA ENSTİTÜSÜ DERGİSİDİR 23. Kojima, S., Funahashi, T., Sakamoto, T. et al. (2003) The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89, 667 24. Nakamura, Y., Shimada, K., Fukuda, D. et al. (2004) Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 90, 528–533 25. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. (1999) “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.” Biochem Biophys Res Commun 257:79–83. 26. Cnop M., Havel P.J., Utzschneider K.M.,Carr D.B., Sinha M.K.,Boyko E.J., et al. (2003) “Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.” Diabetologia 46:459–469 27. Ouchi N.,Kihara S., Funahashi T., Matsuzawa Y., Walsh K. (2003) “Obesity, adiponectin and vascular inflammatory disease.” Curr Opin Lipidol 14:561–566. 28. Fasshauer M.,Kralisch S.,Klier M., Lossner U.,Bluher M.,Klein J., et al. (2003) “Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes.” Biochem Biophys Res Commun 301:1045–1050. 29. Lindsay R.S.,Resnick H.E.,Zhu J., Tun M.L., Howard B.V.,Zhang Y., et al. (2005) “Adiponectin and coronary heart disease: the Strong Heart Study.” Arterioscler Thromb Vasc Biol 25:e15–e16. 30. Lawlor D.A.,Davey Smith G., Ebrahim S.,Thompson C., Sattar N. (2005) “Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women.” J Clin Endocrinol Metab 90:5677–5683. 31. Sattar N., Wannamethee G., Sarwar N., Tchemova J., Cherry L., Wallace A.M. et al. “Adiponectin and coronary heart disease: a prospective study and metaanalysis.” Circulation in press. 32. [994]Lindsay R.S.,Resnick H.E.,Zhu J., Tun M.L., Howard B.V.,Zhang Y., et al. (2005) “Adiponectin and coronary heart disease: the Strong Heart Study.” 87 AZİZ SANCAR DENEYSEL TIP ARAŞTIRMA ENSTİTÜSÜ DERGİSİDİR Arterioscler Thromb Vasc Biol 25:e15–e16. 33. [995] Lawlor D.A.,Davey Smith G., Ebrahim S.,Thompson C., Sattar N. (2005) “Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women.” J Clin Endocrinol Metab 90:5677–5683. 34. [996] Sattar N., Wannamethee G., Sarwar N., Tchemova J., Cherry L., Wallace A.M. et al. “Adiponectin and coronary heart disease: a prospective study and metaanalysis.” Circulation in press.
Yıl 2016,
Cilt: 6 Sayı: 11, 79 - 89, 01.06.2016
Öz
Kaynakça
- 1. Shin Jh, Kim Jh, Lee Wy, Shim Jy. “The Expression Of Adiponectin Receptors And The Effects Of Diponectin And Leptin On Airway Smooth Muscle Cells.” Yonsei Med J. 2008 Oct 31;49(5):804-10. 2. Bringham Cl, Muller Jl, Palupu A, Spinelli Jj, Anis Aa, 1999 “The Cost Of Obesity İn Canada.“ Canadian Medical Association Journal. 160:483-488 3. Kopelman Pg., 2000. “Obesity As A Medical Problem.” Nature 6;404(6778):635-643 4. Coşkun H., 2002. “Türkiye’deki Obezite Sıklığı(Prevelansı)” 5. Farmer J.A., Gotto A.: “Risk Factor For Coronary Artery Disease.” In: Braunwald Heart Disease A Textbook Of Cardiovascular Medicine. 4th Ed An Hbj International Edition, Volume 1, Chapter 37, 1125-55, 1992. 6. Ross R.: “The Pathogenesis Of Atherosclerosis.” In : Braunwald Heart Disease A Textbook Of Cardiovascular Medicine. 4th Edition An Hbj International Edition, Volume 1, Chapter 36, 1106-24, 1992. 7. Havel Pj: “Control Of Energy Homeostasis And İnsulin Action By Adipocyte Hormones: Leptin, Acylation Stimulating Protein, And Adiponectin.” Curr Opin Lipidol 13: 51-59, 2002 8. Clasen R, Schupp M, Foryst- Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U. “Ppargamma-Activating Angiotensin Type-1 Receptor Blockers İnduce Adiponectin.” Hypertension. 2005 Jul;46(1):137-43. Epub 2005 Jun 6. 9. Haluzík M, PařÍzková J, Haluzík MM: “Adiponectin And İts Role İn The Obesity-İnduced İnsulin Resistance And Related Complications.” Physiol Res 53: 123-129, 2004b. 10. Steppan Cm, Baıley St, Bhat S, Brown Ej, Banerjee Rr, Wrıght Cm, Patel Hr, Ahıma Rs, Lazar Ma: “The Hormone Resistin Links Obesity To Diabetes.” Nature 409: 307-312, 2001. 11. Hotta K, Funahashı T, Arıtay, Takahashı M, Matsuda M, Okamoto Y, Iwahashı H, Kurıyama H, Ouchı N, Maeda K, Nıshıda M, Kıhara S, Sakaı N, Nakajıma T, Hasegawa K, Muraguchı M, Ohmoto Y, Nakamura T, Yamashıta S, Hanafusa T, Matsuzawa Y: “Plasma Concentrations Of A Novel, Adipose-Specific Protein, Adiponectin, İn Type 2 Diabetic Patients”. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000. 12. Arıtay, Kıhara S, Ouchı N, Takahashı M, Maeda K, Mıyagawa J, Hotta K, Shımomura I, Nakamura T, Mıyaoka K, Kurıyama H, Nıshıda M, Yamashıta S, Okubo K, Matsubara K, Muraguchı M, Ohmoto Y, Funahashı T, Matsuzawa Y: “Paradoxical Decrease Of An Adipose-Specific Protein, Adiponectin, İn Obesity.” Biochem Biophys Res Commun 257: 79-83, 1999. 13. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. 85 AZİZ SANCAR DENEYSEL TIP ARAŞTIRMA ENSTİTÜSÜ DERGİSİDİR “Adiponectin: A Key Adipocytokine İn Metabolic Syndrome.” Clin Sci (Lond). 2006;110: 267–278. 14. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsu- Zawa Y, Matsubara K. Cdna “Cloning And Expression Of A Novel Adipose Specific Collagen-Like Factor, Apm1 (Adipose Most Abundant Gene Transcript 1).” Biochem Biophys Res Commun 1996. 221:286-289. 15. Hu E, Liang P, Spiegelman Bm. “Adipoq İs A Novel Adipose Specific Gene Dysregulated İn Obesity”. J Biol Chem 1996. 271:10697-10703. 16. Vasseur F, Meyre D, Froguel P. “Adiponectin, Type 2 Diabe- Tes And The Metabolic Syndrome: Lessons From Human Genetic Studies.” Expert Rev Mol Med 2006. 8:1-12. 17. Kadowaki T, Yamauchi T. “Adiponectin And Adiponectin Receptors.” Endocr Rev 2005. 26:439-451. 18. Kharroubi I, Rasschaert J, Eizirik Dl, Cnop M. “Expression Of Adiponectin Receptors İn Pancreatic Cells.” Biochem Biophys Res Commun 2003. 312:1118-1122. 19. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno Nh, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, And Kadowaki T. “Cloning Of Adiponectin Receptors That Mediate Antidiabetic Metabolic Effects.” Nature 423: 762–769, 2003. 20. Ouchi, N., Kihara, S., Arita, Y. et al. (1999) “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.” Circulation 100, 2473–2476 21. Pischon, T., Girman, C. J., Hotamisligil, G. S., Rifai, N., Hu, F. B. and Rimm, E. B. (2004) “Plasma adiponectin levels and risk of myocardial infarction in men.” JAMA, J. Am. Med. Assoc. 291, 1730–1737 22. Schulze, M. B., Shai, I., Rimm, E. B., Li, T., Rifai, N. and Hu, F. B. (2005) “Adiponectin and future coronary heart disease events among men with type 2 diabetes.” Diabetes 54, 534–539 86 AZİZ SANCAR DENEYSEL TIP ARAŞTIRMA ENSTİTÜSÜ DERGİSİDİR 23. Kojima, S., Funahashi, T., Sakamoto, T. et al. (2003) The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89, 667 24. Nakamura, Y., Shimada, K., Fukuda, D. et al. (2004) Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 90, 528–533 25. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. (1999) “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.” Biochem Biophys Res Commun 257:79–83. 26. Cnop M., Havel P.J., Utzschneider K.M.,Carr D.B., Sinha M.K.,Boyko E.J., et al. (2003) “Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.” Diabetologia 46:459–469 27. Ouchi N.,Kihara S., Funahashi T., Matsuzawa Y., Walsh K. (2003) “Obesity, adiponectin and vascular inflammatory disease.” Curr Opin Lipidol 14:561–566. 28. Fasshauer M.,Kralisch S.,Klier M., Lossner U.,Bluher M.,Klein J., et al. (2003) “Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes.” Biochem Biophys Res Commun 301:1045–1050. 29. Lindsay R.S.,Resnick H.E.,Zhu J., Tun M.L., Howard B.V.,Zhang Y., et al. (2005) “Adiponectin and coronary heart disease: the Strong Heart Study.” Arterioscler Thromb Vasc Biol 25:e15–e16. 30. Lawlor D.A.,Davey Smith G., Ebrahim S.,Thompson C., Sattar N. (2005) “Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women.” J Clin Endocrinol Metab 90:5677–5683. 31. Sattar N., Wannamethee G., Sarwar N., Tchemova J., Cherry L., Wallace A.M. et al. “Adiponectin and coronary heart disease: a prospective study and metaanalysis.” Circulation in press. 32. [994]Lindsay R.S.,Resnick H.E.,Zhu J., Tun M.L., Howard B.V.,Zhang Y., et al. (2005) “Adiponectin and coronary heart disease: the Strong Heart Study.” 87 AZİZ SANCAR DENEYSEL TIP ARAŞTIRMA ENSTİTÜSÜ DERGİSİDİR Arterioscler Thromb Vasc Biol 25:e15–e16. 33. [995] Lawlor D.A.,Davey Smith G., Ebrahim S.,Thompson C., Sattar N. (2005) “Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women.” J Clin Endocrinol Metab 90:5677–5683. 34. [996] Sattar N., Wannamethee G., Sarwar N., Tchemova J., Cherry L., Wallace A.M. et al. “Adiponectin and coronary heart disease: a prospective study and metaanalysis.” Circulation in press.
Toplam 1 adet kaynakça vardır.
Ayrıntılar
| Konular | Sağlık Kurumları Yönetimi |
|---|---|
| Bölüm | Makale |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Haziran 2016 |
| Yayımlandığı Sayı | Yıl 2016 Cilt: 6 Sayı: 11 |
